Financings

Celsion Corp. raised $13 million in a registered direct offering and $5.4 million in a private placement.

Coronado Biosciences Inc. filed a Form-10 with the SEC as a non-IPO route to public listing.

gIcare Pharma Inc. raised $7 million in Series A financing to develop a colonic analgesic.

NeoStem Inc. is raising about $16.5 million in a public offering of stock and warrants.

Protox Therapeutics Inc. entered a $15 million loan agreement with Oxford Finance LLC.

SARcode Bioscience Inc. raised $44 million in a Series B financing.

Ventrus Biosciences Inc. raised $45 million in a public stock offering.

Deals

Allergan Inc. acquired dermatology company Vicept Therapeutics Inc. for $275 million.

AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. are merging in a $686 million all-stock deal.

BioSante Pharmaceuticals Inc. licensed a melanoma vaccine to the John P. Hussman Foundation.

Icagen Inc. is being acquired by partner Pfizer Inc. for $56 million.

NeoStem Inc. acquired privately held stem cell firm Amorcyte Inc. for $18 million.

Vical Inc. signed a potential $130 million deal with Astellas Pharma Inc. for TransVax in transplant.

. . . And More

AstraZeneca plc's Brilinta (ticagrelor) gained FDA approval for acute coronary syndromes.

AstraZeneca plc and Bristol-Myers Squibb Co.'s diabetes drug dapagliflozin got rejected by an FDA advisory panel.

Dynavax Technologies Corp.'s hepatitis B vaccine Heplisav met its Phase III endpoints, but had a manufacturing inconsistency.

Exelixis Inc. said partner Bristol-Myers Squibb Co. handed back rights to XL281 .

Nabi Biopharmaceuticals Inc.'s smoking cessation vaccine NicVAX failed Phase III.

Transcept Pharmaceuticals Inc. is eliminating 45 percent of its work force.